Table 1.
Characteristics | n = 222 | % |
---|---|---|
Glioblastoma multiforme (GBM) | 121 | 54% |
secondary glioblastoma (GBMsec) | 18 | 15% |
preoperative samples (GBMsec preop) | 9 | 50% |
postoperative samples (GBMsec postop) | 9 | 50% |
primary glioblastoma (GBMprim) | 103 | 85% |
preoperative samples (GBMprim preop) | 69 (10) 1 | 67% |
recurrence-related analysis | 69 | 67% |
original tumour | 54 | 78% |
recurrence | 15 | 22% |
therapy involvement analysis | 69 | 67% |
patients before therapy | 54 | 78% |
patients with therapy | 15 | 22% |
survival analysis | 27 | 39% |
>65 Years | 11 | 41% |
≤65 Years | 16 | 59% |
high MMP-9 level (≥28 ppm) | 17 | 63% |
low MMP-9 level (<28 ppm) | 10 | 37% |
postoperative samples (GBMprim postop) | 14 (10) 1 | 33% |
Brain Metastasis (BM) | 37 | 17% |
carcinoma planocellulare (BMplano) | 13 | 35% |
adenocarcinoma (BMadeno) | 24 | 65% |
preoperative samples (BMpreop) | 27 (6) 2 | 73% |
postoperative samples (BMpostop) | 10 (6) 2 | 27% |
Meningioma (M) | 28 | 13% |
meningioma Grade I (M_I) | 20 | 71% |
meningioma Grade II (M_II) | 8 | 29% |
Control (CTRL) | 36 | 16% |
lumbar disc herniation | 36 | 16% |
male | 16 | 44% |
female | 20 | 56% |
Percentages indicate the participation rates within each statistical analyses; 1 Number of GBM patients involved in paired t-test; 2 Number of BM patients involved in paired t-test.